Oncolytics completes enrollment in phase 1 Reolysin cancer trial

By E. Janene Geiss

Philadelphia, Aug. 23 - Oncolytics Biotech Inc. said Wednesday it has completed patient enrollment in its phase 1 U.S. clinical trial investigating the systemic delivery of Reolysin to treat patients with advanced cancers.

A total of 18 patients were treated in the phase 1 trial with Reolysin at escalating dosages of 1x10(8), 3x10(8), 1x10(9), 3x10(9), 1x10(10) or 3x10(10) TCID(50).

A maximum tolerated dose was not reached and the treatment appears to have been well-tolerated by the patients, according to a company news release.

The clinical trial is an open-label, dose-escalation study in which a single dose of Reolysin was administered intravenously to patients diagnosed with selected advanced or metastatic solid tumors that are refractory to standard therapy or for which no curative standard therapy exists.

The primary objective of the study is to determine the maximum-tolerated dose, dose-limiting toxicity and safety profile of Reolysin.

Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumor activity.

Oncolytics is a Calgary, Alta., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.